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Ted D WadeAbstract
We review traits of reusable clinical data and offer a typology of clinical repositories with a range of known
examples. Sources of clinical data suitable for research can be classified into types reflecting the data’s institutional
origin, original purpose, level of integration and governance. Primary data nearly always come from research studies
and electronic medical records. Registries collect data on focused populations primarily to track outcomes, often
using observational research methods. Warehouses are institutional information utilities repackaging clinical care
data. Collections organize data from more organizations than a data warehouse, and more original data sources
than a registry. Therefore even if they are heavily curated, their level of internal integration, and thus ease of use,
can be less than other types. Federations are like collections except that physical control over data is distributed
among donor organizations. Federations sometimes federate, giving a second level of organization. While the size,
in number of patients, varies widely within each type of data source, populations over 10 K are relatively numerous,
and much larger populations can be seen in warehouses and federations. One imagined ideal structure for research
progress has been called an “Information Commons”. It would have longitudinal, multi-leveled (environmental
through molecular) data on a large population of identified, consenting individuals. These are qualities whose
achievement would require long term commitment on the part of many data donors, including a willingness to
make their data public.
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Recent years have seen repeated calls [1-4] to make better
use of both existing and future biomedical data in order
to more quickly and economically advance research and
patient care. This is accompanied by advocacy for non-
experimental designs and techniques that improve the
validity of using existing observations in research [5,6],
and for innovative exploratory or data mining [7-9]
studies. There is heightened awareness of problems [10]
such as cultural or legal barriers to data sharing, and of
technical problems of reuse, such as lack of syntactic or
semantic comparability of data, or poor accessibility or
preservation of data.
Such critiques can give the impression that suitable
clinical, phenotypic data of appropriate volume and
condition are difficult to locate. This paper counters
that hypothesis by offering a sampling of major clinical/
phenotypic sources, along with a classification system
to help would-be users understand more about generalCorrespondence: wadet@njhealth.org
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unless otherwise stated.issues of availability and usability. The review is mostly
focused on sources in the United States, where complex
delivery and research systems are accompanied by a
variety of data repository solutions.Repository traits and types
Descriptions of the sources will refer to repository traits
(Table 1) that make them more or less useful and available
for research. The first two traits are quantitative ones that
we use later (Figure 1) to compare all the repository types.
The first trait is the number of patients or research sub-
jects observed. Users of our own data warehouse have
made it clear that the number of potential patients is a pri-
mary concern for researchers when judging whether a data
source is useful. Though in Figure 1 these numbers vary
across eight orders of magnitude, they still fail to capture
much of the variability of data volume because the
numbers of observations made on each patient also vary
widely. For strictly clinical databases, the number of ob-
servations per patient might vary from the 10’s to the
low 1000’s. For biomolecular data, typical data points
per patient are often in the 10 K’s to 100 K’s. The rangeis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Data repository traits that are relevant to data reuse
Repository trait Definition
Sample size Number of patients represented.
Data generations from source Number of times data or access methods were modified, where generation 1 is original source data.
Level of integration Extent of structuring that organizes data for query.
Longitudinal observations Containing observations over multiple times per patient.
Personally identified Capable of delivering direct patient identifiers to research projects.
Research accessibility Extent to which data are accessible to researchers, whether within or outside of a home institution.
Data quality Accuracy, completeness and consistency of data expression.
Linked biosamples Having available biosamples linked to phenotypic information.
Biomolecular data Having biomolecular/omics data linked to phenotypic information.
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to a high end of sequencing entire genomes. Even being
conservative, the number of data objects one might find
in a re-usable clinical database right now could vary from
roughly 102 for a clinical pilot study to 1011 (our estimate







AHRQ  Handbook examples
UK Biobank
Pfizer ePlacebo
CTSA integrated data repositories
Vanderbilt BioVU DNA databank






2012 AHRQ census of PBRNs
2003 Indiana survey of PBRNs
HMO Research Network
Mini-Sentinel








Figure 1 Biomedical repository types and sizes. Each type has exempla
distinct patients represented. When a cell has a number, it is the coefficien
with no number is either part of a known range, or part of an order of ma
of modification of data or access methods, where the original source data
exemplars only appear if data for estimating their size are available.Because reuse of data nearly always requires some re-
organization and curation, our second dimension of the
resources (Table 1) is the number of generations that data
are removed from their primary sources. The first gener-
ation is “primary” data – as first recorded for clinical or
research purposes. Subsequent generations modify dataenerations
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t of the log: e.g., a 2.7 in the 2 column means 2.7 × 102. A filled cell
gnitude estimated range. Generations from source refers to generations
is generation 1. Types and exemplars are discussed in the text. Specific
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ation for networks of federated data networks.
Data repositories vary in their levels of integration
(Table 1), i.e., the extent of internal organizing structures
that provide such functions as: locations, indices, catalogs,
semantic translations or equivalences, consistent syntactic
structures and links to external information [12]. The level
of integration of a data repository affects its usefulness by
constraining how readily one may make a detailed global
query for any subset of its contents. Integration structures
that support one use case for a repository may not support
other use cases as well. It is often hard to learn about
the level of integration of a data source until you start
to use it.
Having longitudinal data on individuals is a part of
many observational designs, and is needed for research
into outcomes, efficacy and many mechanistic studies,
[2,3]. Most repositories thus have longitudinal observa-
tions (Table 1). To build such a database you need some
way to link observations on the same identified person.
Therefore most repositories contain personally identified
data, but, because of privacy concerns, they often release
only de-identified data. Difficulties in the de-identification
process can cause some data to be omitted in a dataset
[10]. A lack of direct identifiers in a data collection or
federation (terms defined in Table 2) could prevent linking
of data for some patients [13].
Data repositories vary in how they restrict which re-
searchers, or which types of research, can use them
(Table 1). While some are fairly open, others are restricted
either to employees of an institution or to members of
some research network. Thus a researcher’s access to data
riches might require a collaboration with someone who
has direct access.
Data quality (Table 1) and its fitness for a particular
purpose is a multidimensional problem [14] and a com-
mon concern for data reuse [13]. Users of a repository
need to be aware of the data’s original purpose and of
what has been done to improve its fitness for reuse or
being compared with other data.Table 2 Types of clinical data repositories
Repository type Definition
Study A database that collects observations for a specific clinical
EHR A database of observations made as a result of direct hea
Registry Observations collected and organized for the purpose of
Associated studies are either multiple or longterm and ev
Warehouse A repository that adds levels of integration and quality to
flexible queries for multiple uses. Is broader in application
Collection A library of heterogeneous data sets from more organizat
help users find a particular data set, but not to query for d
Federation A repository distributed across multiple locations, where e
responsible for making the data comparable with the dat
Repositories vary based on the purpose, origin, control and integration of their dataSome repositories gain value by having biosamples avail-
able and linked to clinical data [15]. Others gain value by
linking biologically derived data to clinical observations
[11,16] (Table 1).
The US (United States) National Institutes of Health
recently announced a “Big Data to Knowledge” (BD2K)
initiative [17]. How big are available resources, and what
makes them useful? We try to address this by a typology
of repositories (Figure 1) based on how and why they are
constructed (Table 2). The classifications are not absolute
because one could readily classify some data repositories
in more than one category.Studies and EHRs
The first generation databases in Figure 1 are of two
types: databases collected for individual research studies,
and electronic health records (EHRs). As we estimate in
Figure 1 the size range of EHRs is wide, since it includes
installations in small medical practices and long-term
databases in large healthcare organizations. The structure
and function of EHRs tends to limit their direct use in re-
search, so EHR data used in research is typically extracted
first into a registry or data warehouse (see below). Reposi-
tories of personal electronic health records exist, and we
include an example, the genome-centered 23andMe, in
which 90% of subjects allow some research use of their
data [18].
In Figure 1 we estimate clinical studies to have sizes
from the 10’s to 1000’s of patients. Research study data
have generally higher quality, in terms of consistency
and completeness, due to the elaborate processes used
to assure this [2,3]. However, their data semantics (the
meaning of the observations) may often be narrow and
poorly suited for comparison to other data [19]. Research
data are very expensive to acquire, practically limiting the
sample size, but genome-wide association studies have
tended to raise sample sizes. Research studies can some-
times include some second-generation data derived from
regular clinical care.research study.
lth care.
studying or guiding particular outcomes on a defined population.
olving over time.
the primary (research or clinical) data of a single institution, to support
than a registry.
ions than a warehouse or more sources than a registry. Organized to
ata combined across data sets.
ach location retains control over access to its own data, and is
a of other locations.
.
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In its comprehensive handbook on building registries the
Agency for Healthcare Research and Quality (AHRQ)
says ([5] page 1) that “A patient registry is an organized
system that uses observational study methods to collect
uniform data (clinical and other) to evaluate specified
outcomes for a population defined by a particular disease,
condition, or exposure, and that serves one or more
predetermined scientific, clinical, or policy purposes”.
Registries thus exemplify observational methods in their
construction and use. They are often of hybrid gener-
ation (both first and second) because they might include
primary data from other sources. The purposes served
by a registry can be quite broad, and – because their data
are of higher quality than routine clinical care observa-
tions – they could potentially be used for purposes that
were not part of their original plan. Vandenbrouke [6]
noted that collecting data for prospective follow-up stud-
ies (a typical registry purpose) “is so huge an undertaking
for the study of causes of disease that researchers only
begin such investigations when they are really necessary
to confirm or refute something important”. Thus the
reuse of expensive, high-quality registry data seems like
a good idea.
The size of registries varies a lot. The size of the 36
registries used as examples in the comprehensive AHRQ
Handbook [5] ranged over 5 orders of magnitude, with
61% of them in the range from 1 K to 100 K patients.
The UK Biobank [20] is essentially a massive, very general-
purpose registry of 500 K patients and their biospecimens
that has recently become available for research. It is expen-
sive enough to require support from multiple governments,
a major charity and a major foundation.Warehouses
Clinical data warehouses are repositories of information
from clinical, and sometimes research, records from a
single organization, such as a care provider or a payer. A
warehouse normally has a high level of integration to
allow very flexible queries of its content. They typically
have the ability to de-identify queried data, or to allow
query for frequencies of records. Both are methods making
researcher access easier [21]. Warehouses operate [22] as
sort of an information utility for their host institutions,
allowing cohort discovery for prospective research (both
observational and experimental) and supporting retro-
spective queries for quality of care work, pilot studies, and
case–control research. As a second-generation data source,
warehouses attempt to standardize their incoming data for
more effective use [22], in a process known generically in
the database industry as ETL, meaning “extract, transform,
and load”. The growth of clinical data warehouses has
benefitted greatly from having a standard, publically-available platform called i2b2 [23]. The i2b2 platform has
crossed over to also be used in building registries [24].
A 2010 survey [21] of academic health centers receiving
U.S. Clinical and Translational Science Awards found 22
institutional data warehouses in 35 institutions. The num-
ber of patients in a warehouse (Figure 1) ranged from
43 K to 10 M, with a median of 1.6 M. These numbers
reflect the generally large clinical patient populations at
many research hospitals.
Vanderbilt’s BioVU DNA data warehouse is noteworthy
because of its incorporation of a biobank and derived gen-
omic data [25]. BioVU links more than 150,000 unique
genetic samples [26] to de-identified medical records. Part
of its successful growth is due to having patient participa-
tion be decided on an opt-out basis, a new approach that
is said to satisfy ethical concerns while increasing diversity
of the research population, and thus wider application of
research’s benefits [25]. The resource has been used for
over 15 genome-wide association studies, and for correl-
ation of adverse drug effects with genome scans.
Even larger, in fact the largest (in terms of patients)
single database of any kind in this review is the US Centers
for Medicare and Medicaid Services (CMS) database
[27] of inpatient and outpatient data on citizens over
65. Figures for enrollment varied from 41 M in 2002 to
49 M in 2012 [28]. This is payer, not clinical, data but
includes much useful detail on diagnoses, demograph-
ics, the services provided and the costs of those services.
The comprehensive nature of the data, especially for
hospitalization, makes this database very useful for
longitudinal outcomes research. The database is being
restructured with “big data” technology [29] to increase
its usability and capacity.
Collections
A collection is a data repository that combines, into one
location, data that originated from multiple independent
sources. So a collection involves more organizations than
a data warehouse and/or more original data sources than
a registry. The term, collection, was chosen by analogy
with holdings in a library, with a catalog (the metadata)
holding the collection together and focusing access on the
individual books or journals. The usual heterogeneity of
datasets in a collection means that their structure, codings
and meanings may make them less integrated or compar-
able than data in warehouses or registries. It may be quite
impractical to index collection data so that, for example,
a researcher could search 1000 different studies for the
values of a particular type of laboratory test. When such
integration is not practical it is instead useful to standardize
and index metadata – e.g., whether a study is known to
be a randomized controlled trial, or whether it has single
nucleotide polymorphism data. The metadata catalog at
least lets a database user know that by examining selected
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needed details.
Prototypical collections (Figure 1) are the Gene Ex-
pression Omnibus (GEO) [30] and the NIH’s Database
of Genotypes and Phenotypes, dbGaP [11]. GEO is a
large international collection of functional genomics
data, including data from many species and studies with
many purposes. The data on the approximately half a
million humans are de-identified, with considerable
variability in their phenotypic or experimental characteris-
tics, but still very much usable. This usability was shown,
for example, in a large disease/gene expressions correl-
ation study [31]. dbGaP is human and genotype-focused,
with more emphasis on useful, searchable detail about
phenotypes. But it is also a collection because search is
still a hierarchical, multi-step, affair.
The eMERGE (Electronic Medical Records and Genom-
ics) Network [15] collects biosamples, SNP data, and phe-
notypes computed from EMR data, all from a national
consortium of 10 institutions. The eMERGE collection is
more highly curated, with an integration level more like a
data warehouse. The integration includes the development
of algorithms to extract standard phenotypes (e.g., [32])
from disparate medical record systems. The facility sup-
ports a number of different collaborations, so its data
structures are optimized for those. But it also allows
members to query across the entire subject population
and obtain counts of subjects having combinations of
ICD9 and CPT codes, stratified by demographics (per-
sonal communication). Note that compared to the collec-
tions mentioned above, eMERGE is an order of magnitude
smaller, possibly reflecting the cost of its higher level of
integration.
Federations
Data federations are somewhat like collections except
that a larger share of control remains with the organiza-
tions contributing their data. Usually data do not leave
those organizations, except in summary form, when some-
one queries the federation for data. The informatics work
to make data comparable across the network is itself
distributed among the participant organizations. Thus
each participant needs to re-organize their primary data
for sharing. After this, the addition of a step to aggregate
information across the network means that federations
normally use third-generation data. This 3-step process
(EHR to warehouse to federation) was also described as
prototypical by Kahn and Weng (13). The gigantic (and
paradoxically named) Mini-Sentinel federation for product
safety surveillance [33] is our largest example of any data
system, but its possible use outside of its designed purpose
is still undetermined.
Another very large federation is the HMO Research
Network (HMORN) [34] of 18 health maintenanceorganizations, covering 14 M patients in the United
States and Israel. A sub-network of the HMORN is
the Kaiser Permanente consortium, which is reported
to have over 9 M patients [35]. The HMORN shares
[36] with Mini-Sentinel a technology base, PopMedNet
[37] that allows data holders to independently decide
whether to respond to particular queries from the net-
work. HMORN exemplifies how research networks grow
and intersect. Members of HMORN have collaborated on
hundreds of peer-reviewed projects, with varying partners
in and out of the network [38]. Currently HMORN mem-
bers participate in at least 10 consortia, each involving at
least 10 or more members, some including non-network
partners as well. In fact there are 13 HMORN members
out of the 33 organizations in Mini-Sentinel.
One type of data federation is rather common, taking
the form of “practice-based research networks” (PBRNs)
of small to medium ambulatory care providers that are
[39] “laboratories for primary care research and dissemin-
ation” (see, e.g. [40]). In Figure 1 we show two inventories
of PBRNs. A 2003 survey [41] by Indiana University con-
tacted 86 PBRNs representing 1,871 practices covering a
total of 14.7 M patients. Most were open to research initi-
ated by non-members. A 2012 [39] inventory by the US
Agency for Healthcare Research and Quality (AHRQ),
which strongly encourages PBRNs and supports them in
various ways, counted more than 150 networks, at over
17 K locations, with 55 K clinicians serving about 46 M
patients. Those counts were used in Figure 1 to make a
rough estimate of the range of patient numbers per PBRN.
There seems to be growth in the number and coverage of
PBRN networks in the US over a decade, and the number
of available patients is very large.
The evolution of PBRNs includes networks of networks,
which means fourth generation data. The one example
shown (Figure 1) out of several found, DARTNet [42], is
a federation that contains 9 distinct networks covering
5 million patients. As with the growth of the HMORN
meta-network, evolution into larger or second-order
federations is facilitated by adoption of common tech-
nology or data models.
The information commons as a super-collection
The collection concept has been taken to something like
an ultimate conclusion with the recent US Institute of
Medicine proposal [3] for a national Information Commons
and Knowledge Network. This proposes to build a giant
database from data collected during normal medical care.
It would bypass the clinical trials bottleneck to produce
breakthrough efficiency in building the knowledge needed
for individualized, precision medicine. Among its critical
features would be:
 Massive size and high levels of integration.
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linking data from multiple phenotypic and
environmental levels (clinical, exposures, genome,
epigenome, microbiome, etc.) by retention of
longitudinal data on identified individual patients.
 Gradual growth to solve structural, security, and
regulatory/governance issues while incorporating
new types of data as they become part of regular
clinical care.
 Feedback of knowledge obtained from derived
studies and the general literature into a Knowledge
Network.
The committee said that only a “massive re-orientation
of … information systems” to vertical integration of data
on individuals will allow the kinds of research needed. In
Figure 1 we assume that the Information Commons would
be at most an order of magnitude larger than existing
large collections like dbGaP or GEO because of the system
integration and governance costs. The report’s strong pos-
ition for identified data linkage contrasts with a workshop
[10] from the same Institute of Medicine on research data
sharing. The latter continues with the common assump-
tion that de-identification of data is necessary before col-
lection and reuse. However they did note that patient
engagement in, awareness of, and sharing the benefits of,
research needs to increase for multiple reasons, not the
least being respect for patient dignity.
How might the “massive re-orientation” that is needed
for the Information Commons evolve? The authors [3]
noted that the development of dbGap – even though it
is de-identified and less integrated – is evidence that the
Information Commons project is possible. One research
organization, Sage Bionetworks [43], has developed a
“Portable Legal Consent” to enable patients, with one
document, to donate any of their data at any time. The
consent is being used with their open, web-based platform
called BRIDGE, creating small disease-focused communi-
ties of patients to prototype “citizen participation” in
multi-leveled research. The organization is also supplying
a free data federation platform, Synapse, for researcher
collaboration. Synapse has already enabled an instance of
unprecedented cooperation and data sharing [44] among
60 different research projects in The Cancer Genome
Atlas program.
The Information Commons would need continuing and
comprehensive coverage on data from a wide variety of
patients. Because data in a person’s clinical history accu-
mulate over time and from different sources, new infor-
mation can only be linked by matching on individual
identifiers. Research studies would not necessarily need
access to those identifiers as long as all data on each in-
dividual were linked. However, the inclusion of detailed
genetic information would mean that re-identificationof research data would be feasible [45]. Therefore a
data donor would have a significant risk of loss of
confidentiality.
We already know that patients will share personal health
information in certain circumstances, such as when they
have debilitating chronic diseases (e.g., PatientsLikeMe
[46]). Quite a few people will also entrust private health
information to a third party repository [18] and even allow
some research on their data. So the question for the In-
formation Commons is: would enough people donate
nearly all of their identified health data on a continuing
(longitudinal) basis to be used in future research of any
legitimate type? To obtain the needed patient consents
and participation there would have to be an educational
effort to promote the values of personal data sharing –
for which appealing arguments [43,45] have been advanced.
So far the only repository of public, identifiable data, both
genomic and phenotypic, is the Personal Genome Project,
which is also a biorepository. The number of participants
is still fairly low at 2,781 (Figure 1 and [16]).
Whether we are at “a tipping point and historic moment
of scientific opportunity” [43] to build the Information
Commons may depend on how readily the concept
spreads and acquires resources that might have otherwise
gone towards more traditional approaches to research.
One sign in the Commons’s favor is the recent US Patient-
Centered Outcome Research Institute’s plan [47] to con-
struct a large federation called the “PCORnet National
Patient-Centered Clinical Research Network”, to be used
for both observational and interventional comparative ef-
fectiveness studies and possibly for other types of research,
all at a national scale. Data will be longitudinal and on-
going. One component of the network is a set of existing
large health systems and federations, called CDRNs, who
will contribute large amounts of routine clinical care data,
suitably curated to a standard. The other component is a
set of diverse patient-centered networks called PPRNs that
are focused on particular disease conditions, some of them
rare. These will collect both clinical and patient-generated
data, with a focus on patient involvement (“patient-
centered”). In our terminology, the PPRNs will be like
a federation of registries, but also having a connection
to the CDRN federation of federations. PCORnet is tack-
ling big issues relevant to the formation of an Information
Commons, including governance, privacy, standardization,
sustainability and patient involvement in, and consent for,
research. For PCORnet to be a nucleus for growth of
the Commons would also require the eventual addition
of biological levels of data, as well as wider consent to
make personal data public.
Conclusions
Research and clinical care have provided large and growing
pools of reusable clinical data in a variety of institutional
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of at least 10 K, with quite a few having 1–4 orders of
magnitude more. The utility of these repositories var-
ies: in the levels of internal organization that affect
their usability, in whether they also contain linked tis-
sue or bio-molecular data, and in the extent to which
they are accessible to non-affiliated researchers. The
ideal data source, described by some as an Information
Commons, could only be achieved by advances in regu-
lation, technology and public opinion. Its proponents
think that it would enable a breakthrough in the pro-
gress of biomedical research and its application to hu-
man health.
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